Thymosin beta-4

Mechanism (as reported)

Across the provided sources, thymosin beta-4 is repeatedly associated with actin regulation: it is described as an actin monomer sequestering protein and as participating in modulation of actin polymerization dynamics in cells. Sources also propose that its flexible/unfolded nature may allow recognition of multiple ligands, contributing to pleiotropic functions. (PMIDs: 12852258, 17495248)

Key findings (each cites a source)

• Research described Tβ4 as a low molecular weight, naturally occurring peptide that is reported to be released by platelets, macrophages, and many other cell types after injury, with roles described in protecting cells and tissues from further damage and reducing apoptosis, inflammation, and microbial growth. [PMID 22074294]
• One source reports that Tβ4 binds to actin and promotes cell migration, including mobilization, migration, and differentiation of stem/progenitor cells and formation of new blood vessels, and also reports it decreases myofibroblast number in wounds, resulting in decreased scar formation and fibrosis. [PMID 22074294]
• A protein-interaction-focused source states thymosin beta-4 is a small 5-kDa protein with diverse activities, including actin monomer sequestration, antiinflammatory activity, and inhibition of bone marrow stem cell proliferation; it also states that only effects on the actin cytoskeleton have an explanation based on identified molecular interactions. [PMID 12852258]
• A structural/functional discussion source reports that thymosin beta-4 is largely unfolded or completely unfolded in solution and suggests that flexible structure may facilitate recognition of numerous ligands, potentially explaining pleiotropic functions. [PMID 12852258]
• A review on the “beta-thymosin enigma” reports that Tβ4 is implicated in modulating availability of actin monomers and that beta-thymosins regulate actin polymerization responses; it also reports that overexpression or addition of Tβ4 (or Tβ10) alters actin cytoskeleton and motility-related cellular functions. [PMID 17495248]
• A review reports that Tβ4 (and Tβ10) expression was investigated over time during human development and in different human organs/tissues using proteomics and immunochemistry, aiming to generate suggestions for roles in health and disease. [PMID 38994967]
• An organoid/model study reported that in Alzheimer disease–related contexts, TMSB4X gene expression significantly decreased in fAD organoid neurons and in AD patients’ excitatory neurons; it further reported that deficits and Aβ formation in fAD organoids were rescued by treatment with Tβ4, and it reports that beneficial effects were also revealed in 5xfAD model mice. [PMID 40816274]
• A regenerative/anti-aging therapy direction review describes investigations in heart as a model system, reporting that developmental expression of TB4 occurs in mouse embryos and that the molecule was reported to promote cardiac cell migration and survival, with additional reported effects on cardiac function and epicardial morphology and gene expression changes consistent with an embryonic state; it also reports epicardial progenitor activation. [PMID 36709593]
• A cardiac remodeling mechanism study reports that after profiling adult mouse hearts following experimental conditions with or without TB4, miR139-5p expression increased and ROCK1 was identified as a potential target; it also reports that ROCK1 protein levels were modulated in vivo and in vitro and that TB4 may reverse or inhibit fibroblast/myofibroblast transformation, with cell-type-specific downstream mechanisms. [PMID 40362372]
• A kidney-disease-focused review states that Tβ4 is a highly conserved 43-amino-acid peptide encoded by the X-linked TMSB4x gene and describes it as the predominant β-thymosin in mammalian cells; it further reports that Tβ4 and its N-terminal metabolite Ac-SDKP are described as mediators of renal injury and repair and discusses evidence for cytoprotection, anti-inflammatory and antifibrotic actions across acute and chronic kidney injury models, along with discussion of challenges such as peptide instability and safety assessment needs. [PMID 41570941]